Biotech entity
Every one of those 4 sits in a single category, pharma. Source depth averages 10.3 original sources per story, versus 3.5 across the same-window beat baseline. Of the tracked stories, 1 of 4 also mention Alkami Technology, the most common co-covered peer.
Last mentioned: Mar 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 25 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 4 sits in a single category, pharma. Source depth averages 10.3 original sources per story, versus 3.5 across the same-window beat baseline. Of the tracked stories, 1 of 4 also mention Alkami Technology, the most common co-covered peer. That works out to roughly 1.3 stories per week across a 22-day span. The 5.8 average consequence score is below the beat benchmark of 6 in the same window. This profile follows 4 Biotech stories mentioning Acadia Pharmaceuticals across the period from February 26, 2026 to March 19, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 279 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Acadia Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Earnings Call
Management hosts a conference call to discuss 2025 performance and 2026 outlook.
Financial Reporting
XOMA files Q4 and Full Year 2025 financial results with the SEC.
Q4 Earnings Call
ACADIA reports strong year-end results and 2026 guidance.
Asset Acquisition
Completion of a significant acquisition of royalty rights from a clinical-stage partner.
Strategic Disclosure
XOMA issues Regulation FD disclosure regarding portfolio updates.
Daybue Stix Launch
Launch of the granule formulation to enhance patient compliance.
Daybue Approval
FDA approves Daybue as the first treatment for Rett syndrome.
Nuplazid Approval
FDA approves Nuplazid for Parkinson's disease psychosis.
XOMA Royalty reported its Q4 and full-year 2025 financial results, highlighting a significant expansion of its royalty portfolio and the continued commercial success of key assets like Vabysmo and Daybue. The company remains focused on its strategic pivot toward becoming a pure-play royalty aggregator in the biotechnology sector.
Source: tickerreport.com · dailypolitical.com
A surge in parental demand for off-label treatments for autism spectrum disorder (ASD) has created a significant rift between families and the medical community. While anecdotal reports drive interest in therapies like GLP-1s and Rett syndrome drugs, physicians cite a lack of robust clinical data and potential safety risks as reasons for their reluctance to prescribe.
ACADIA Pharmaceuticals delivered a strong Q4 performance, underscored by the rapid adoption of Daybue and the resilience of its Parkinson’s franchise. The results highlight a successful transition into a diversified commercial-stage biotech with a clear path to sustained profitability.
Mid-cap biotech and specialty pharma companies are demonstrating strong commercial maturation, led by record-breaking rare disease revenues and strategic consolidation. Key players like Mirum and Acadia are scaling rapidly, while Alkermes’ acquisition of Avadel signals a shift toward aggressive portfolio expansion in the neuroscience space.
Acadia Pharmaceuticals is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
